首页> 美国卫生研究院文献>Oncotarget >Transcriptome and proteome profiling reveals stress-induced expression signatures of imiquimod-treated Tasmanian devil facial tumor disease (DFTD) cells
【2h】

Transcriptome and proteome profiling reveals stress-induced expression signatures of imiquimod-treated Tasmanian devil facial tumor disease (DFTD) cells

机译:转录组和蛋白质组图谱揭示了应激诱导的咪喹莫特治疗的塔斯马尼亚恶魔面部肿瘤病(DFTD)细胞的表达特征

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

As a topical cancer immunotherapy, the toll-like receptor 7 ligand imiquimod activates tumor regression via stimulation of immune cell infiltration and cytotoxic responses. Imiquimod also exerts direct pro-apoptotic effects on tumor cells in vitro, but a role for these effects in imiquimod-induced tumor regression remains undefined. We previously demonstrated that cell lines derived from devil facial tumor disease (DFTD), a transmissible cancer threatening the survival of the Tasmanian devil (Sarcophilus harrisii), are sensitive to imiquimod-induced apoptosis. In this study, the pro-apoptotic effects of imiquimod in DFTD have been investigated using RNA-sequencing and label-free quantitative proteomics. This analysis revealed that changes to gene and protein expression in imiquimod treated DFTD cells are consistent with the onset of oxidative and endoplasmic reticulum stress responses, and subsequent activation of the unfolded protein response, autophagy, cell cycle arrest and apoptosis. Imiquimod also regulates the expression of oncogenic pathways, providing a direct mechanism by which this drug may increase tumor susceptibility to immune cytotoxicity in vivo. Our study has provided the first global analysis of imiquimod-induced effects in any tumor cell line. These findings have highlighted the potential of cell stress pathways as therapeutic targets in DFTD, and will allow for improved mechanistic use of imiquimod as a therapy in both the Tasmanian devil and human cancers.
机译:作为局部癌症免疫疗法,toll​​样受体7配体咪喹莫特通过刺激免疫细胞浸润和细胞毒性反应来激活肿瘤消退。咪喹莫特还可以在体外对肿瘤细胞直接发挥促凋亡作用,但这些作用在咪喹莫特诱导的肿瘤消退中的作用仍然不确定。我们先前证明,来自魔鬼面部肿瘤疾病(DFTD)(威胁塔斯马尼亚魔鬼(Sarcophilus harrisii)生存的可传播癌症)的细胞系对咪喹莫特诱导的细胞凋亡敏感。在这项研究中,已使用RNA测序和无标记定量蛋白质组学研究了咪喹莫特在DFTD中的促凋亡作用。这项分析表明,咪喹莫特处理的DFTD细胞中基因和蛋白质表达的变化与氧化和内质网应激反应的发作以及随后的未折叠蛋白质反应,自噬,细胞周期停滞和凋亡的激活相一致。咪喹莫特还调节致癌途径的表达,提供了一种直接的机制,通过这种机制该药物可以增加体内对免疫细胞毒性的肿瘤敏感性。我们的研究提供了在任何肿瘤细胞系中对咪喹莫特诱导的作用的首次全球分析。这些发现凸显了细胞应激途径作为DFTD中治疗靶标的潜力,并且将改善咪喹莫特在塔斯马尼亚恶魔和人类癌症中作为治疗手段的机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号